Abciximab: benefits for some in ACS

    loading  Checking for direct PDF access through Ovid

Abstract

Abciximab [ReoPro, CentoRx, Centrex] significantly reduces the risk of ischaemic events in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) following pretreatment with clopidogrel 600mg, according to results of the ISAR-REACT 2 trial presented at the 55th Annual Scientific Session of the American College of Cardiology (ACC) [Atlanta, Georgia, US; March 2006], and subsequently published online in JAMA. The multinational trial was conducted in more than 2000 patients, and showed that abciximab was associated with a 25% risk reduction for the combined cumulative incidence of death, myocardial infarction (MI), or urgent target vessel revascularisation within 30 days after PCI; however, the benefits of abciximab appeared to be confined to patients with an elevated troponin level.

Related Topics

    loading  Loading Related Articles